Combined iodine-125 seed strand, portal vein stent, transarterial chemoembolization, lenvatinib and anti-PD-1 antibodies therapy for hepatocellular carcinoma and Vp4 portal vein tumor thrombus: A propensity-score analysis
Frontiers in Oncology · 19.01.2023 · 12
DOI: 10.3389/fonc.2022.1086095 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 19.01.2023. Verfasst von Zi-Han Zhang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Interveintional Radiology, Zhongshan hospital, Fudan, University, Shanghai, China. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
To evaluate the safety and efficacy of interventional therapy (iodine-125[ 125 I] seed strand and portal vein stent [PVS] implantation plus transarterial chemoembolization [TACE]) combined with systemic therapy (lenvatinib plus anti-PD-1 antibody) as first-line treatment for hepatocellular carcinoma (HCC) patients with Vp4 portal vein tumor thrombus (PVTT). Patients and methods From December 2018 to October 2021, 87 HCC patients with Vp4 PVTT were included in this single-center retrospective study. Forty-seven patients underwent interventional therapy combined with lenvatinib and anti-PD-1 antibody (group A), while 40 cases underwent interventional therapy combined with lenvatinib only (group B). Overall response rate (ORR), stent occlusion rates (SOR), median overall survival (OS), median progression-free survival (PFS) and median stent patency time (SPT) were compared between the 2 groups.
Results
The mean intended dose (r = 10 mm; z = 0; 240 days) was 64.9 ± 1.0 Gy and 64.5 ± 1.1 Gy in group A and B, respectively ( p = 0.133). ORR and SOR were significantly different between group A and B (ORR, 55.3% vs 17.5%, p < 0.001; SOR, 12.8% vs 35.0%, p = 0.014). In the propensity-score matching (PSM) cohort, the median OS, median PFS and median SPT were significantly longer in group A compared with group B (32 PSM pairs; OS, 17.7 ± 1.7 vs 12.0 ± 0.8 months, p = 0.010; PFS, 17.0 ± 4.3 vs 8.0 ± 0.7 months, p < 0.001; SPT, not-reached vs 12.5 ± 1.1 months, p = 0.028).
Conclusion
This interventional therapy combined with lenvatinib and anti-PD-1 antibody is safe and effective for HCC patients with Vp4 PVTT.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Interveintional Radiology, Zhongshan hospital, Fudan, University, Shanghai, China.
- Shanghai Institute of Medical Imaging, Fudan University, Shanghai, China.
- National Clinical Research Center of Interventional Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.
Zitieren
APA
Zhang, Z. H., Hou, S. N., Yu, J. Z., Zhang, W., Ma, J. Q., Yang, M. J., Liu, Q. X., Liu, L. X., Luo, J. J., Qu, X. D., & Yan, Z. P. (2023). Combined iodine-125 seed strand, portal vein stent, transarterial chemoembolization, lenvatinib and anti-PD-1 antibodies therapy for hepatocellular carcinoma and Vp4 portal vein tumor thrombus: A propensity-score analysis. Frontiers in Oncology, 12. https://doi.org/10.3389/fonc.2022.1086095
Vancouver
Zhang ZH, Hou SN, Yu JZ, Zhang W, Ma JQ, Yang MJ, et al. Combined iodine-125 seed strand, portal vein stent, transarterial chemoembolization, lenvatinib and anti-PD-1 antibodies therapy for hepatocellular carcinoma and Vp4 portal vein tumor thrombus: A propensity-score analysis. Frontiers in Oncology. 2023;12. doi:10.3389/fonc.2022.1086095
BibTeX
@article{Zhang2023,
author = {Zhang, Zi-Han and Hou, Si-Nan and Yu, Jia-Ze and Zhang, Wen and Ma, Jing-Qin and Yang, Min-Jie and Liu, Qing-Xin and Liu, Ling-Xiao and Luo, Jian-Jun and Qu, Xu-Dong and Yan, Zhi-Ping},
title = {Combined iodine-125 seed strand, portal vein stent, transarterial chemoembolization, lenvatinib and anti-PD-1 antibodies therapy for hepatocellular carcinoma and Vp4 portal vein tumor thrombus: A propensity-score analysis},
journal = {Frontiers in Oncology},
year = {2023},
volume = {12},
doi = {10.3389/fonc.2022.1086095}
}
EUVIMED